Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lobeglitazone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults
Details : Lobeglitazone is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2025
Lead Product(s) : Lobeglitazone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lobeglitazone
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Aclipse Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Aclipse gains worldwide rights to develop CKD’s M107 (lobeglitazone), an oral, small molecule, for gastroparesis and additional indications.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 14, 2023
Lead Product(s) : Lobeglitazone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Aclipse Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Lobeglitazone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Receives DCGI Approval for Type 2 Diabetes Drug to Improve Insulin Resistance
Details : Lobeglitazone is a film-coated tablet made up of Lobeglitazone Sulfate equivalent to Lobeglitazone to improve glycaemic control in adult type 2 diabetes.
Product Name : Lobeglitazone-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2023
Lead Product(s) : Lobeglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lobeglitazone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LOBG contains lobeglitazone and is taken once daily to improve glycaemic control in adult diabetic patients. Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled type 2 diabetes.
Product Name : LOBG
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : Lobeglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable